Skip to main content Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NYSE: EW

Edwards Lifesciences Corporation

Healthcare | Medical - Devices
$81.92 -2.23 (-2.65%) as of 2026-07-15 02:27 UTC
Market Cap$47.6B
EPS (TTM)$1.83

Edwards Lifesciences Corporation (NYSE: EW) is a $47.6B medical - devices company trading at $81.92 (−2.6% today) — 44.8× trailing earnings. Figures from SEC EDGAR and market feeds; updated 2026-07-15 02:27 UTC.

52-Week Range
Low $77.10High $84.74

What Edwards Lifesciences Corporation does

Edwards Lifesciences is a structural heart company that develops medical technologies to treat advanced cardiovascular disease, with a focus on therapies for heart valve disorders and heart failure. The company offers three main product groups: transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, and surgical structural heart products. Its offerings include both catheter-based minimally invasive procedures that do not require open-heart surgery and traditional surgical approaches using bioprosthetic valves and repair devices.

Summarized from Edwards Lifesciences Corporation’s SEC filings · Read the filing ↗

Key facts
Quote
Price$81.92
Change (1D)-2.23 (-2.65%)
Market cap$47.6B
52-week range$77.10 – $84.74
Valuation
P/E (TTM)44.77×
EV/EBITDA31.80×
EPS (TTM)$1.83
Price/book4.60×
Return on equity10.34%
Debt/equity0.06
Returns
52-week return+6.3%
Revenue, margins & earnings
FY2021 Net income: $1.50BFY2021 Taxes & interest: $187MFY2021 Operating expenses: $2.29BFY2021 Cost of revenue: $1.25B$5.23BFY2021FY2022 Revenue: $4.46B — margin split not shown (non-operating gains)$4.46BFY2022FY2023 Revenue: $5.01B — margin split not shown (non-operating gains)$5.01BFY2023FY2024 Revenue: $5.44B — margin split not shown (non-operating gains)$5.44BFY2024FY2025 Net income: $1.07BFY2025 Taxes & interest: $195MFY2025 Operating expenses: $3.47BFY2025 Cost of revenue: $1.33B$6.07BFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
Annual revenue; bands show net, operating, gross margins · Open in Platform →
SEC Filings SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-07-10
  • 2026-07-10Mistras TheodoraCVP, Chief Financial OfficerA87,595—
  • 2026-07-10Mistras TheodoraCVP, Chief Financial OfficerA12,325—
  • 2026-07-10Mistras TheodoraCVP, Chief Financial OfficerA61,800—
Sign in to see all transactions →
Top Institutional Holders (latest 13F)
Source: SEC EDGAR · As of 2026-Q1
  • VANGUARD GROUP INC69,801,468$5.95B-0.8%
  • BlackRock, Inc.47,689,279$3.82B-9.1%
  • VANGUARD CAPITAL MANAGEMENT LLC37,727,792$3.02BNEW
View QoQ ownership changes →
Company news View all →
Questions this page answers

What does Edwards Lifesciences Corporation do?

Edwards Lifesciences is a structural heart company that develops medical technologies to treat advanced cardiovascular disease, with a focus on therapies for heart valve disorders and heart failure.

What is EW's valuation?

EW trades at $81.92, 44.77× trailing earnings, 31.80× EV/EBITDA, as of 2026-07-15.

When did EW last file with the SEC?

Edwards Lifesciences Corporation's most recent SEC filing on record is a 8-K filed 2026-05-08. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-07-15 02:27 UTC. This page is also available as JSON at /api/data?ticker=EW and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for EW and 3,500+ tickers.

Create a free account — keep EW
For your agent
GET /api/data?ticker=EW

This page as JSON via rel="alternate" · REST API docs · MCP server (51 tools) · llms.txt